5-YEAR FOLLOW-UP OF HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY CLL IN PHASE 3 STUDY: SIGNIFICANT SURVIVAL BENEFIT WITH OBLIMERSEN PLUS FLUDARABINE/CYCLOPHOSPHAMIDE IN RESPONDING PATIENTS

被引：0
|
作者：
O'Brien, M. [1 ]
Gribben, J. [2 ]
Cousin, T. [3 ]
Rai, K. [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Inst Canc Res, London, England
[3] Genta Inc, Berkeley Hts, NJ USA
[4] Long Isl Jewish Med Ctr, New Hyde Pk, NY 11042 USA
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0357
引用
收藏
页码：141 / 142
页数：2
相关论文
共 50 条
  • [1] 5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
    O'Brien, Susan
    Moore, Joseph O.
    Boyd, Thomas E.
    Larratt, Loree M.
    Skotnicki, Aleksander B.
    Koziner, Benjamin
    Chanan-Khan, Asher A.
    Seymour, John F.
    Gribben, John
    Itri, Loretta M.
    Rai, Kanti R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) : 5208 - 5212
  • [2] Effect of the addition of oblimersen (Bcl-2 antisense) to fludarabine/cyclophosphamide for relapsed/refractory chronic lymphocytic leukemia (CLL) on survival in patients who achieve CR/nPR: Five-year follow-up from a randomized phase III study
    Rai, K. R.
    Moore, J.
    Wu, J.
    Novick, S. C.
    O'Brien, S. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [3] Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
    Ahn, Inhye E.
    Brander, Danielle M.
    Ren, Yue
    Zhou, Yinglu
    Tyekucheva, Svitlana
    Walker, Heather A.
    Black, Robert
    Montegaard, Josie
    Alencar, Alvaro
    Shune, Leyla
    Omaira, Mohammad
    Jacobson, Caron A.
    Armand, Philippe
    Ng, Samuel Y.
    Crombie, Jennifer
    Fisher, David C.
    LaCasce, Ann S.
    Arnason, Jon
    Hochberg, Ephraim P.
    Takvorian, Ronald W.
    Abramson, Jeremy S.
    Brown, Jennifer R.
    Davids, Matthew S.
    BLOOD ADVANCES, 2024, 8 (04) : 832 - 841
  • [4] Oblimersen plus fludarabine/cyclophosphamide (FC) significantly increases complete remission and overall survival in non-refractory patients (Pts) with relapsed chronic lymphocytic leukemia (CLL): results from a prospective randomized phase 3 trial
    Novick, S.
    O'Brien, S.
    Moore, J.
    Boyd, T.
    Ding, L.
    Rai, K.
    EJC SUPPLEMENTS, 2007, 5 (04): : 346 - 346
  • [5] 5-YEAR FOLLOW-UP OF MINOXIDIL-TREATED REFRACTORY HYPERTENSIVE PATIENTS
    MITCHELL, HC
    PETTINGER, WA
    PREVENTIVE MEDICINE, 1978, 7 (01) : 115 - 115
  • [6] Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited-duration therapy
    Ma, Shuo
    Seymour, John F.
    Brander, Danielle M.
    Kipps, Thomas J.
    Choi, Michael Y.
    Anderson, Mary Ann
    Humphrey, Kathryn
    Al Masud, Abdullah
    Pesko, John
    Nandam, Ruby
    Salem, Ahmed Hamed
    Chyla, Brenda
    Arzt, Jennifer
    Jacobson, Amanda
    Kim, Su Young
    Roberts, Andrew W.
    BLOOD, 2021, 138 (10) : 836 - 846
  • [7] FLUDARABINE, CYCLOPHOSPHAMIDE AND LENALIDOMIDE IN RELAPSED/REFRACTORY PATIENTS WITH CLL, PRELIMINARY RESULTS OF THE PHASE1-2 GIMEMA CLL0606 STUDY
    Mauro, F. R.
    Carella, A. M.
    Vignetti, M.
    Orlando, S. M.
    Liberati, A. M.
    Molica, S.
    Belsito, V.
    Cortellezzi, A.
    Zaia, F.
    Specchia, G.
    Tosi, P.
    Campanelli, M.
    Iannella, E.
    Trastulli, F.
    Nanni, M.
    Marinelli, M.
    Graziosi, A.
    Cuneo, A.
    Guarini, A.
    Foa, R.
    HAEMATOLOGICA, 2014, 99 : 319 - 319
  • [8] Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study
    Ahn, Inhye E.
    Farooqui, Mohammed Z. H.
    Tian, Xin
    Valdez, Janet
    Sun, Clare
    Soto, Susan
    Lotter, Jennifer
    Housel, Stephanie
    Stetler-Stevenson, Maryalice
    Yuan, Constance M.
    Maric, Irina
    Calvo, Katherine R.
    Nierman, Pia
    Hughes, Thomas E.
    Saba, Nakhle S.
    Marti, Gerald E.
    Pittaluga, Stefania
    Herman, Sarah E. M.
    Niemann, Carsten U.
    Pedersen, Lone B.
    Geisler, Christian H.
    Childs, Richard
    Aue, Georg
    Wiestner, Adrian
    BLOOD, 2018, 131 (21) : 2357 - 2366
  • [9] A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial
    Grosicki, Sebastian
    Lech-Maranda, Ewa
    Govind Babu, Kanakasetty
    Rybka, Justyna
    Litvinskaya, Elena
    Loscertales, Javier
    Kriachok, Iryna
    Kloczko, Janusz
    Rekhtman, Grygoriy
    Homenda, Wojciech
    Blonski, Jerzy
    Stefanelli, Tommaso
    Vincent, Ghislaine
    Banerjee, Hiya
    Robak, Tadeusz
    LEUKEMIA & LYMPHOMA, 2020, 61 (07) : 1748 - 1751
  • [10] Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
    O'Brien, Susan
    Moore, Joseph O.
    Boyd, Thomas E.
    Larratt, Loree M.
    Skotnicki, Aleksander
    Koziner, Benjamin
    Chanan-Khan, Asher A.
    Seymour, John F.
    Bociek, R. Gregory
    Pavletic, Steve
    Rai, Kanti R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (09) : 1114 - 1120
12345